Metabolomics Analysis Reveals Both Plant Variety and Choice of Hormone Treatment Modulate Vinca Alkaloid Production in Catharanthus Roseus.

22 April 2020, Version 2
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

The medicinal plant Catharanthus roseusproduces numerous secondary metabolites of interest for the treatment of many diseases—most notably for the terpene indole alkaloid (TIA) vinblastine, which is used in the treatment of leukemia and Hodgkin’s lymphoma. Historically, methyl jasmonate (MeJA) has been used to induce TIA production, but in the past, this has only been investigated in either whole seedlings, cell culture, or hairy root culture. In this work, we investigate the induction capabilities of MeJA and ethylene, a different phytohormone, in both the shoots and roots of two varieties of C. roseus. Using LCMS and RT-qPCR, we demonstrate the importance of variety selection, as we observe markedly different induction patterns of important TIA precursor compounds. Additionally, both phytohormone choice and concentration have significant effects on TIA biosynthesis. Finally, our study suggests that several early-induction pathway steps as well as pathway-specific genes are likely to be transcriptionally regulated. Our findings highlight the need for a complete set of ’omics resources in commonly used C. roseus varieties.

Keywords

Catharanthus roseus
Vinca alkaloids
methyl jasmonate treatment
ethephon treatment
qRT-PCR expression analysis
LCMS

Supplementary materials

Title
Description
Actions
Title
Croseus paper ACS SI final
Description
Actions
Title
Croseus paper Plant Direct final
Description
Actions
Title
croseus eth meja supp figs
Description
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.